文献速递流行病学与生物统计临床试验与 GCP

低碳与极低碳水化合物饮食对2型糖尿病缓解的疗效与安全性:系统综述与荟萃分析

Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data.
PubMed 文献 · BMJ · 2021-01-13

该系统综述与荟萃分析纳入23项随机临床试验共1357例2型糖尿病患者,评估低碳(<130 g/天或<2000 kcal/天的26%)与极低碳(<10%热量来自碳水)饮食至少12周的疗效与安全性。6个月时低碳饮食组HbA1c<6.5%的缓解率高于对照(57% vs 31%;风险差0.32,95%CI 0.17–0.47),但12个月缓解数据稀疏;体重、甘油三酯和胰岛素敏感性6个月改善明显、12个月减弱。

要点

  • 低碳饮食6个月可使部分2型糖尿病患者HbA1c<6.5%缓解,但使用胰岛素者缓解明显减少。
  • 6个月体重、甘油三酯和胰岛素敏感性改善明显,12个月时效果减弱。
  • 12个月生活质量与低密度脂蛋白胆固醇出现临床重要但未达统计学显著的恶化。

核心结论

  • 基于中至低确定性证据,坚持低碳饮食6个月可能使2型糖尿病患者获得糖尿病缓解且无不良后果。
  • 局限性包括糖尿病缓解定义仍有争议,以及长期低碳饮食的疗效、安全性和饮食满意度尚不明确。

研究设计与样本

  • 系统综述与荟萃分析,检索CENTRAL、Medline、Embase、CINAHL、CAB及灰色文献至2020年8月25日。
  • 纳入23项随机临床试验共1357例参与者,40.6%的结局判定为低偏倚风险。
  • 纳入标准为成人2型糖尿病患者接受低碳(<130 g/天或<2000 kcal/天的26%)或极低碳(<10%热量来自碳水)饮食至少12周。

主要发现

  • 6个月时低碳饮食组HbA1c<6.5%缓解率高于对照(76/133(57%) vs 41/131(31%);风险差0.32,95%CI 0.17–0.47;8项研究,n=264,I2=58%)。
  • 采用HbA1c<6.5%且不用药定义缓解时,效应量较小且无统计学显著性。
  • 可信亚组评估显示,纳入使用胰岛素患者的研究中低碳饮食的缓解率明显降低。
  • 12个月缓解数据稀疏,范围从小的效应到糖尿病风险轻微增加。
  • 6个月体重、甘油三酯和胰岛素敏感性出现大的临床重要改善,12个月减弱;6个月生活质量无显著差异,12个月生活质量和低密度脂蛋白胆固醇出现临床重要但未达统计学显著的恶化。

关键数值与推荐

  • 低碳饮食定义:<130 g/天或<2000 kcal/天的26%。
  • 极低碳饮食定义:<10%热量来自碳水化合物。
  • 主要结局包括糖尿病缓解(HbA1c<6.5%或空腹血糖<7.0 mmol/L,伴或不伴降糖药使用)、体重减轻、HbA1c、空腹血糖和不良事件。

临床怎么用

  • 对2型糖尿病患者可考虑短期(6个月)低碳饮食以促进糖尿病缓解和代谢改善。
  • 使用胰岛素的患者采用低碳饮食实现缓解的可能性较低,需个体化评估。
  • 长期应用需关注生活质量和低密度脂蛋白胆固醇变化,并加强随访。

局限性

  • 糖尿病缓解的定义尚存争议,影响结果解读。
  • 12个月缓解数据稀疏,长期疗效和安全性证据不足。
  • 长期低碳饮食的饮食满意度不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy and safety of low carbohydrate diets (LCDs) and very low carbohydrate diets (VLCDs) for people with type 2 diabetes. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Searches of CENTRAL, Medline, Embase, CINAHL, CAB, and grey literature sources from inception to 25 August 2020. STUDY SELECTION: Randomized clinical trials evaluating LCDs (<130 g/day or <26% of a 2000 kcal/day diet) and VLCDs (<10% calories from carbohydrates) for at least 12 weeks in adults with type 2 diabetes were eligible. DATA EXTRACTION: Primary outcomes were remission of diabetes (HbA1c <6.5% or fasting glucose <7.0 mmol/L, with or without the use of diabetes medication), weight loss, HbA1c, fasting glucose, and adverse events. Secondary outcomes included health related quality of life and biochemical laboratory data. All articles and outcomes were independently screened, extracted, and assessed for risk of bias and GRADE certainty of evidence at six and 12 month follow-up. Risk estimates and 95% confidence intervals were calculated using random effects meta-analysis. Outcomes were assessed according to a priori determined minimal important differences to determine clinical importance, and heterogeneity was investigated on the basis of risk of bias and seven a priori subgroups. Any subgroup effects with a statistically significant test of interaction were subjected to a five point credibility checklist. RESULTS: Searches identified 14 759 citations yielding 23 trials (1357 participants), and 40.6% of outcomes were judged to be at low risk of bias. At six months, compared with control diets, LCDs achieved higher rates of diabetes remission (defined as HbA1c <6.5%) (76/133 (57%) v 41/131 (31%); risk difference 0.32, 95% confidence interval 0.17 to 0.47; 8 studies, n=264, I2=58%). Conversely, smaller, non-significant effect sizes occurred when a remission definition of HbA1c <6.5% without medication was used. Subgroup assessments determined as meeting credibility criteria indicated that remission with LCDs markedly decreased in studies that included patients using insulin. At 12 months, data on remission were sparse, ranging from a small effect to a trivial increased risk of diabetes. Large clinically important improvements were seen in weight loss, triglycerides, and insulin sensitivity at six months, which diminished at 12 months. On the basis of subgroup assessments deemed credible, VLCDs were less effective than less restrictive LCDs for weight loss at six months. However, this effect was explained by diet adherence. That is, among highly adherent patients on VLCDs, a clinically important reduction in weight was seen compared with studies with less adherent patients on VLCDs. Participants experienced no significant difference in quality of life at six months but did experience clinically important, but not statistically significant, worsening of quality of life and low density lipoprotein cholesterol at 12 months. Otherwise, no significant or clinically important between group differences were found in terms of adverse events or blood lipids at six and 12 months. CONCLUSIONS: On the basis of moderate to low certainty evidence, patients adhering to an LCD for six months may experience remission of diabetes without adverse consequences. Limitations include continued debate around what constitutes remission of diabetes, as well as the efficacy, safety, and dietary satisfaction of longer term LCDs. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020161795.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Goldenberg JZ, Day A, Brinkworth GD, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021. PMID: 33441384. doi:10.1136/bmj.m4743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。